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B-cell post-transplant lymphoproliferative disorders (PTLD) are classified as early lesions,
polymorphic lymphomas (P-PTLD) and monomorphic lymphomas (M-PTLD). These
morphologic categories are thought to reflect a biologic continuum, although supporting
genetic data are lacking. To gain better insights into PTLD pathogenesis, we characterized
the phenotypes, immunoglobulin (Ig) gene alterations and non-Ig gene (BCL6, RhoH/TTF,
c-MYC, PAX5, CIITA, BCL7A, PIM1) mutations of 21 PTLD, including an IM-like lesion, 8
P-PTLD and 12 M-PTLD. Gene expression profile analysis was also performed in 12 cases.
All PTLD with clonal Ig rearrangements showed evidence of germinal centre (GC) transit
based on the analysis of Ig and BCL6 gene mutations, and 74% had a non-GC phenotype
(BCL6MUM1þ). Although surface Ig abnormalities were seen in 6/19 (32%) PTLD,
only three showed ‘crippling’ Ig mutations indicating other etiologies for loss of the B-cell
receptor. Aberrant somatic hypermutation (ASHM) was almost exclusively observed in
M-PTLD (8/12 vs. 1/8 P-PTLD) and all three recurrent cases analysed showed additional
mutations in genes targeted by ASHM. Gene expression analysis showed distinct clustering
of PTLD compared to B-cell non-Hodgkin lymphomas (B-NHL) without segregation of
P-PTLD fromnon-GCM-PTLD or EBVþ fromEBV PTLD. The gene expression pattern
of PTLD appeared more related to that of memory and activated B-cells. Together, our
results suggest that PTLD represent a distinct type of B-NHL deriving from an antigen
experienced B-cell, whose evolution is associated with accrual of genetic lesions. Copyright
# 2008 John Wiley & Sons, Ltd.
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Introduction
Post-transplant lymphoproliferative disorders (PTLD)
encompass a heterogeneous group of lymphocytic pro-
liferations, the vast majority of which are of B-cell origin.
The current WHO classification categorizes them as early
lesions, polymorphic lymphomas (P-PTLD) and mono-
morphic lymphomas (M-PTLD). Virtually, all early lesions
are polyclonal and they appear to lack any known
molecular alterations [1]. Many P-PTLD and most
M-PTLD are clonal [1,2]. Compared to P-PTLD, M-PTLD
harbour more karyotypic abnormalities, have a higher
frequency of alterations of protooncogenes and carry
mutations in a number of tumour-suppressor genes [1,3,4].
Mutations in genes due to aberrant somatic hypermutation
(ASHM), a recently identified B-cell specific mechanism
of genetic instability, have been reported to occur
exclusively in M-PTLD [5,6]. The presence of distinct
as well as shared cytogenetic aberrations among P-PTLD
and M-PTLD [4] suggests that certain M-PTLD might
arise as independent primary neoplasms, while others may
represent progression of P-PTLD. The relationship of
P-PTLD to M-PTLD, however, remains unknown.
Our understanding of the cellular origin of PTLD also
remains unclear. A limited number of studies have shown that
the vast majority of cases bear an imprint of germinal centre
(GC) transit, as evidenced by the presence of somatically
mutated immunoglobulin (Ig) genes, and most have non-GC
immunophenotypes (BCL6MUM1þ) [2,7,8]. However,
more sensitive approaches, such as gene expression profiling,
which have significantly advanced our knowledge of B-cell
non-Hodgkin lymphoma (B-NHL) biology, have not been
systematically applied to the study of PTLD.
The pathogenesis of PTLD is commonly associated with
Epstein–Barr virus (EBV) infection, although in more
recent studies 23–42% of PTLD have been reported to be
EBV [2,9]. It has been proposed that EBV PTLD may
be similar to B-NHL of immunocompetent hosts [10]; yet,
a number of them respond to decreased immunosuppres-
sion, suggesting that immune deregulation plays a role in
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the pathogenesis of at least a subset of EBV PTLD [9]. A
minority of PTLD also lack surface B-cell receptor (BCR)
and it is speculated that EBV-encoded proteins can
substitute for BCR signalling and survival of the abnormal
clones [11]. The relationship of EBV PTLD to EBVþ
PTLD or B-NHL occurring in immunocompetent individ-
uals is not known at present.
To gain better insights into the pathogenesis of PTLD,
we performed comprehensive phenotypic and genetic
characterization of 21 PTLD. Gene expression profiles of a
subset of cases were also analysed and compared to other
types of B-NHL and cells representing normal B-cell
maturational stages.
Materials and methods
Case selection and morphologic analysis
We searched our departmental database to identify PTLD
for which frozen tissue samples were available. Frozen
sections were reviewed prior to and after obtaining tissue
for molecular studies, to assess tumour content and
ensure morphologic representation, and only cases with
>90% lesional composition were used. Sections of
formalin-fixed, paraffin-embedded tissue from the corre-
sponding cases were stained with haematoxylin and
eosin for morphologic review. PTLD were classified
according to the current WHO criteria [12]. This study was
approved by the Institutional Review Board of Columbia
University.
Immunohistochemistry, in situ hybridization and
flow cytometry
Immunohistochemical (IHC) stains were performed on
paraffin-embedded tissue sections after moist heat-induced
antigen retrieval, using an autostainer (Universal staining
system, DAKO, Carpinteria, CA) and the primary
antibodies listed in Table 2. The Envision Plus kit (DAKO)
was used for detection. Staining for BLIMP-1 and
activation-induced deaminase (AID) was performed as
previously described [13,14].
Cases were scored as positive if >20% cells expressed
the analysed antigen, except for LMP1, EBNA2 and
BZLF1, where percentage of cellular expression was
recorded.
In situ hybridization for EBV-encoded small RNAs
(EBER) was performed using the manufacturer’s protocol
(INFORM EBER, Ventana, Tucson, AZ).
Three or four colour flow cytometric analysis (FACScan;
BD Biosciences, San Diego, CA) was performed using a
comprehensive panel of antibodies against B- and T-cell
antigens, including Ig light (IgL) and heavy chains (IgH),
according to standard methods. Data were analysed using
the Cell Quest software (BD Biosciences).
DNA and RNA extraction
Genomic DNA and total RNAwere extracted from frozen
tissue according to standard methods. In all PTLD and in
selected matched non-neoplastic tissue specimens, DNA
was also extracted from paraffin-embedded tissue using the
QIAamp DNA mini Kit (QIAGEN, Valencia, CA).
Analysis of IgVH genes
PCR amplification of the Ig heavy chain variable region
(VH) genes was performed using DNA extracted from
frozen tissue initially with IgVH gene family specific
(VH1–6) primers that hybridize to framework region (FR) 1
sequences and an antisense JH primer mix. If no clonal
IgVH gene rearrangement was obtained, DNA was
amplified with VH1,3,4 primers that hybridize to the IgVH
leader (L) region (sequences for all primers have been
previously reported [15,16]). PCR products were purified
and sequenced as described [17], and sequences were
compared to the most homologous germline VH genes in
the IMGT (https://imgt.cines.fr) and IgBLAST (http://
www.ncbi.nlm.nih.gov/igblast/) databases. The presence
of IgVH rearrangements was also determined using FR3
primers and DNA extracted from paraffin-embedded tissue
as previously described [18].
The ratio of replacement to silent mutations in the
complementarity determining regions and FRs was analys-
ed using the multinomial distribution model available at
www-stat.stanford.edu/immunoglobulin [19]. Determi-
nation of antigen selection was based on the analysis of
FR mutations since interpretation of complementarity
determining region mutations is controversial [20].
Analysis of BCL6, PIM1, PAX5, RhoH/TTF, c-MYC,
CIITA and BCL7A
The oligonucleotide sequences used for amplification of
the BCL6, PIM1, PAX5, RhoH/TTF, c-MYC, CIITA and
BCL7A 50 sequences and the genomic regions amplified are
described in Supplemental Table 1. These regions
correspond to the intervals previously shown to harbour
>95% of all BCL6 mutations detected in B-NHL [21] and
>90% of mutations affecting the remaining six genes in
diffuse large B-cell lymphomas (DLBCL) [6] (L. P.,
unpublished data). Purified amplicons were sequenced
directly as described [17] and compared to the correspond-
ing germline sequences (Supplemental Table 1) as
previously reported [6]. Nucleotide changes due to
previously reported polymorphisms or present in paired
normal DNA (where available) were excluded from the
calculation of mutation frequencies [6].
Generation of gene expression profiles
and data analyses
Gene expression profile analysis was performed on 12
PTLD (1 IM-like lesion, 5 P-PTLD and 6 M-PTLD). A
case each of IM-like lesion and M-PTLD of GC phenotype
were included for analysis; the former, since cellular
composition of the interfollicular areas in such lesions
is morphologically indistinguishable from P-PTLD, and
the latter, to determine any overriding effect of the
post-transplant status (effect of immunosuppressive medi-
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cations on the lymphoproliferations or their microenvir-
onment) on the pattern of segregation of PTLD.
Suboptimal RNA quality and insufficient numbers of
distinct morphologic types of M-PTLD (e.g. BL)
precluded analysis of the remaining cases. Complementary
RNAwas prepared as previously described and hybridized
to HG-U95Av2 microarrays (Affymetrix, Santa Clara, CA)
[22]. Gene expression values were determined by the
GCOS 1.4 Microarray Suite 5.0 software (Affymetrix)
using the Global Scaling option. In conjunction with
previously generated expression profile data of other
B-NHL subsets (derived from B-cells at different matura-
tional stages), including EBV DLBCL (n¼ 22; 14
centroblastic and 8 immunoblastic), follicular lymphoma
(FL, n¼ 6), Burkitt lymphoma (BL, n¼ 7; 1 EBVþ and 6
EBV), and hairy cell leukaemia (HCL, n¼ 4) [23,24], a
hierarchical clustering algorithm based on the average-
linkage method was used to generate the dendrogram in
Figure 1 [25]. Expression values of the selected genes were
normalized to have a zero mean value and unit standard
deviation, and the distance between two individual samples
was calculated by Pearson distance analysis.
Supervised analysis was performed using the Genes@-
Work software platform [26]. PTLD gene expression
profiles were compared to mantle cell lymphoma (MCL,
n¼ 7), HCL (n¼ 8), chronic lymphocytic leukaemia
(CLL, n¼ 10), FL (n¼ 6), BL (n¼ 7), DLBCL, including
centroblastic (n¼ 15) and immunoblastic (n¼ 8) subtypes,
and purified normal B-cell subsets (5 naı¨ve, 5 memory and
10 GC) [17,23,27]. Cell type classification was performed
as previously described [27]. Briefly, the classifier is a
scoring function based on a set of differentially expressed
genes between two phenotypes (higher score implies closer
relatedness of the test sample to the phenotype set).
Statistical analysis
Fisher’s exact test and Student’s t-test were performed to
evaluate differences between datasets consisting of
categorical and numerical variables, respectively, and a
p-value< 0.05 was considered significant. Where




Twenty-one PTLD from 18 patients (10M, 8F), including 3
recurrent PTLD, were studied (Table 1). Seven patients
presented with nodal and 11 with extranodal disease.
Median age at initial diagnosis was 21 years (mean 27.5
years, range 2–64 years) and the median time from
transplant to initial diagnosis was 7.5 years (mean 6.0
years, range 0.3–17 years). P-PTLD occurred significantly
earlier than M-PTLD (3.1 vs. 8.7 years, p¼ 0.02). Six
patients are currently alive 1.7–5 years (median 2.6 years,
mean 2.8 years) following initial presentation and 11
patients died 1 month–16 years (median 1.2 years, mean
2.9 years) post-diagnosis, 6 of PTLD and 5 of other causes.
All three patients whose recurrent PTLD were analysed
had variable durations of remissions between recurrences
(1.2, 1.7 and 14 years).
Morphologic and phenotypic analysis
PTLD cases were classified as IM-like lesion (n¼ 1),
P-PTLD (n¼ 8) and M-PTLD (n¼ 12). M-PTLD were
further classified as DLBCL (n¼ 10) and BL (n¼ 2); the
DLBCL were predominantly composed of centroblast-
like cells. Morphologic features of the 12 PTLD used for
gene expression profiling are shown in Supplemental
Figure 1.
The results of IHC staining are shown in Table 2. The
neoplastic cells in all 7 P-PTLD tested and in 7/10 (70%)
DLBCL were CD10-/BCL6/MUM1þ/CD138; these
cases were classified as having a non-GC (post-GC)
phenotype (Table 1) [28]. Three of 10 (30%) DLBCL and
both BL had a GC phenotype (CD10/BCL6þ/MUM1/
CD138). Neoplastic cells in all PTLD expressed PAX5
and CD79a, and all except one were OCT2þ; diminished
(n¼ 4) or absent (n¼ 1) CD20 expression was seen in five
cases (2/7, 29% P-PTLD, 3/12, 25% M-PTLD) by IHC
staining and flow cytometry. One OCT2þDLBCL lacked
OCT2 expression on recurrence. One of 7 (14%) P-PTLD
and 9/12 (75%) M-PTLD (p¼ 0.02) expressed PU.1.
Figure 1. Unsupervised hierarchical clustering performed on a
representative panel of B-NHL, including 22 diffuse large B-cell
lymphomas (DLBCL), 6 follicular lymphomas (FL), 7 Burkitt
lymphomas (BL), 4 hairy cell leukaemias (HCL) and 12 PTLD;
5 polymorphic (P-PTLD), 6 monomorphic (M-PTLD) and 1
IM-like lesion (case numbers shown correspond to PTLD in
Table 1). Clustering is based on the expression of 333 genes.
(Colour scale identifies relative gene expression changes normal-
ized by the standard deviation—zero representing the mean
expression level of a given gene across the panel)
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PTLD with a non-GC phenotype showed weak PU.1
staining, in contrast to PTLD with a GC phenotype
(moderate to strong PU.1 staining), suggesting a corre-
lation of PU.1 expression with GC phenotype, similar to
DLBCL of immunocompetent individuals [29]. Neoplastic
cells of 3/12 (25%) M-PTLD expressed BLIMP-1, while
only plasma cells expressed BLIMP-1 in P-PTLD. One
DLBCL that was HLA-DR by IHC (and dim HLA-DRþ
by flow cytometry) had an aggressive course similar to that
reported for HLA-DR DLBCL of immunocompetent
hosts [30]. Cytoplasmic staining for AID, an enzyme
required for SHM and class switch recombination [31],
was seen only in M-PTLD (0/7 vs. 10/12, p< 0.005). Only
a minority of nuclei in each case (rare—5%) showed AID
expression. There was no evidence of human herpes virus 8
infection as assessed with a stain for latency-associated
nuclear antigen (LANA).
Flow cytometric assessment of IgL and surface IgH
(sIgH) expression performed in 19 and 8 PTLD,
respectively, demonstrated IgL restriction in 8/19 (42%)
PTLD. A dominant sIgH was detected in 5/8 (63%) PTLD.
Absent or diminished sIgL expression was seen in 6/19
(32%) PTLD (3 P-PTLD, 3 M-PTLD); however, mono-
typic cytoplasmic light chains and sIgH were detected in 2
of these cases (Table 1).
EBV infection
Evidence of EBV infection (EBERþ) was found in 11/21
(52%) samples, including the IM-like lesion, 5/8 (63%)
P-PTLD, and 5/12 (42%)M-PTLD (4/10 DLBCL, 1/2 BL).
One EBERþ (and OCT2þ) M-PTLD was EBER (and
OCT2) on recurrence 1.7 years later. The types of viral
latency are shown in Table 1. The IM-like lesion showed
only rare (up to 5/HPF) scattered EBERþ/LMP1/
EBNA2 cells (latency I), while 4/5 (80%) P-PTLD
and 3/5 (60%) M-PTLD exhibited latency type-III
infection (LMP1þ/EBNA2þ). The number of LMP1þ
and EBNA2þ cells, however, varied significantly, indi-
cating heterogeneity in latency types within a given PTLD,
as shown previously [32]. One case each of a P-PTLD and
M-PTLD had latency type-II (LMP-1þ/EBNA2) and the
EBERþ BL had latency type-I infection. All 5 EBVþ
P-PTLD and 2/5 (40%) EBVþ M-PTLD showed variable
BZLF1 (lytic phase protein) expression, similar to previous
reports (Table 2) [32].
The majority of non-GC PTLD were EBVþ (9/14) and
the majority of GC PTLD were EBV (4/5); however, the
correlation between phenotype and EBV infection did not
reach statistical significance (p¼ 0.14). There was no
significant difference in the mean time from transplant to
initial presentation between EBVþ and EBV PTLD (5.2
vs. 7.2 years, p¼ 0.42). AID expression was observed
more frequently in EBV PTLD, although the difference
was not statistically significant (7/9 vs. 3/10, p¼ 0.07).
Analysis of IgVH rearrangements and mutations
Clonal IgVH gene rearrangements were detected in the
majority of PTLD (16/21, 76%) and all except one
harboured somatic mutations (mean frequency 9.2%, range
3.7–19.3%) (Table 3, Supplemental Table 2). The case
lacking IgVH gene mutations had mutations in BCL6 (case
#7, Table 3). Overall, these findings indicate an origin of
PTLD from GC experienced B-cells. There was no
significant difference in the average IgVH mutation
frequency between P-PTLD (7.7%) and M-PTLD
(10.3%, p¼ 0.38) or between EBV PTLD (10.6%) and
EBVþ PTLD (7.5%, p¼ 0.26).
Potentially functional Ig genes were predicted in 13
(81%) of the 16 clonally rearranged PTLD (5/6 P-PTLD
and 8/10 M-PTLD, Supplemental Table 2). The remaining
three (19%) cases displayed an original in-frame
rearrangement that had acquired crippling mutations:
one of these, an EBVþ P-PTLD, had a 295 (bp) deletion
involving FR1 and FR2; two other samples, representing
clonally related EBV M-PTLD from the same patient,
had a 1 bp deletion in the FR3 region, resulting in a
frameshift with premature stop codon. All these three cases
showed absent sIgL expression (and sIgH in one case
evaluated) by flow cytometry. Notably, virtually all
mutated functional rearrangements (11/12) showed lower
than expected number of replacement FR mutations,
indicating selection due to antigen pressure.
Analysis of BCL6 mutations
In agreement with previous studies, BCL6 mutations were
seen in 14/21 (67%) PTLD (Table 3) [2,3]. A total of
46 independent mutations were detected (mutations in
>1 sample from the same patient were counted once),
corresponding to an average mutation frequency of
0.11/100 bp in the mutated cases (range, 0.06–0.45/
100 bp). Of these, the majority were represented by single
bp substitutions (n¼ 43, 18 transitions, 25 transversions,
ratio 0.72) and three were deletions.
No significant differences were observed between
P-PTLD and M-PTLD with respect to total number of
cases carrying BCL6 mutations (5/8, 63% vs. 9/12, 75%,
p¼ 0.6) and average mutation frequency (0.12/100 bp vs.
0.35/100 bp, p¼ 0.19). The presence (or frequency) of
BCL6 mutations also did not correlate with the type of
organ transplanted, immunosuppression, site of PTLD
(nodal vs. extranodal), phenotype, EBV infection or AID
expression. Contrary to a prior study [3], the presence of
BCL6 mutations showed no correlation with clinical
outcome. However, patients who died from disease had a
significantly higher mutation frequency compared to those
who are alive or died from other causes (0.32/100 bp vs.
0.05/100 bp, p¼ 0.03).
Analysis of genes targeted by ASHM
To examine the role of ASHM in the pathogenesis and
progression of PTLD, we sequenced the 50 region of six
non-Ig genes previously identified as ASHM targets,
including two (CIITA and BCL7A) that have not been
previously reported (L. P., unpublished observation). No
mutations were seen in the IM-like lesion and this case was
excluded from further analysis, since a clonal population
Copyright  2008 John Wiley & Sons, Ltd. Hematol Oncol 2008; 26: 199–211
DOI: 10.1002/hon
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Copyright  2008 John Wiley & Sons, Ltd. Hematol Oncol 2008; 26: 199–211
DOI: 10.1002/hon


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Copyright  2008 John Wiley & Sons, Ltd. Hematol Oncol 2008; 26: 199–211
DOI: 10.1002/hon
Molecular analysis of B-cell PTLD 205
was not detected. Mutations affecting at least one gene
were found in 9/20 (45%) PTLD samples from six patients
(Table 3). PAX5was mutated in 1/20 (5%), RhoH/TTF in 4/
20 (20%), c-MYC in 4/18 (22%), BCL7A in 2/20 (10%) and
CIITA in 4/20 (20%) PTLD. No PIM1 mutations were
observed. In total, 25 independent mutations were seen,
consisting of 21 single bp substitutions (13 transitions, 8
transversions, ratio 1.63), three deletions and one
duplication.
ASHM was significantly more frequent in M-PTLD than
in P-PTLD (8/12 vs. 1/8 mutated cases, p¼ 0.028), and
correlated with AID expression (8/10 vs. 0/9, p< 0.005).
When considering EBV status, ASHM was observed more
frequently in EBV PTLD, both with regard to total number
of cases (6/10 vs. 3/10, p¼ 0.4) and mutation load (21 vs. 4
events, p¼ 0.05). No correlations were seen between ASHM
and the type of organ transplanted, immunosuppression, site
of PTLD or phenotype. Notably, all three recurrent PTLD
acquired additional mutations in at least one gene, compared
to the initial sample. Although, not statistically significant, a
greater number of patients who died from disease had
evidence of ASHM compared to those who died of other
causes or are alive (4/6, 66.7% vs. 2/10, 20%, p¼ 0.1). The
former also had a higher number of mutations (20 vs. 5
events, p¼ 0.07), with similar mean follow up durations for
the two groups (31.5 vs. 32.7 months, p¼ 0.96).
Gene expression profile analysis
To investigate whether PTLD are characterized by a
distinct gene expression signature, we compared gene
expression profiles of 12 PTLD with 39 B-NHL samples
representative of lymphomas of GC/post-GC derivation.
Unsupervised hierarchical clustering showed that, with the
exception of the M-PTLD with GC phenotype and the
IM-like lesion, all PTLD segregated as a separate group
(Figure 1). Additionally, PTLD expression profiles were
also different from CLL, MCL [23,27] and marginal zone
B-cell lymphomas (GB, unpublished data). Thus, non-GC
PTLD appear to represent a distinct type of B-NHL.
Supervised analysis, performed to identify genes
differentially expressed between PTLD and normal or
transformed B-cells, detected four genes whose expression
levels were significantly higher in PTLD (PRDM1/
BLIMP-1, XBP-1, IFITM3 and PCMT1) and only one
gene (C19ORF6), of unknown function, which was
expressed at lower levels (Figure 2).
Both unsupervised and supervised analyses failed to
distinguish P-PTLD from non-GC M-PTLD or EBVþ
PTLD (n¼ 8) from EBV PTLD (n¼ 4) (Figure 1 and
data not shown).
Finally, in an attempt to better define the cell of origin
of PTLD, we applied a classification procedure that
measures the relatedness of PTLD gene expression profiles
to those of normal B-cell subsets [27]. PTLD expression
profiles were first compared to the gene expression signature
that distinguishes GC (centroblasts and centrocytes) from
non-GC (naı¨ve and memory) B-cells. This analysis showed
that PTLD are significantly more similar to non-GC B-cells
(Figure 3A, E). On comparing PTLDwith naı¨ve andmemory
B-cells, PTLD appeared more related to memory B-cells
(Figure 3B, E). Lastly, we evaluated the relationship of
PTLD to memory B-cells versus EBV-immortalized
lymphoblastoid cell lines (LCL), representative of activated
B-cells, or multiple myeloma (MM) cell lines, representative
of terminally differentiated plasma cells. In both analyses,
the PTLD expression profile appeared significantly more
similar to that of LCLs (Figure 3C–E).
Discussion
The present study was aimed at elucidating the molecular
histogenesis of PTLD by performing a comprehensive
immunophenotypic, genetic and genome-wide expression
analysis on a panel of PTLD representative of the
polymorphic and monomorphic subtypes. Our findings
Figure 2. Supervised analysis to identify differentially expressed genes between PTLD (5 polymorphic, 6 monomorphic and 1 IM-like
lesion) and a representative panel of normal and neoplastic B-cells, which consists of 7 mantle cell lymphomas (MCL), 8 hairy cell
leukaemias (HCL), 7 Burkitt lymphomas (BL), 10 chronic lymphocytic leukaemias (CLL), 6 follicular lymphomas (FL), 23 DLBCL
(15 centroblastic—CB-DLBCL, 8 immunoblastic—IB-DLBCL), naı¨ve and memory B-cells (5 each), and 10 germinal centre B-cells. In
the matrix, columns represent samples and rows correspond to genes. The scale bar provides visualization of difference in the z-scores
(expression difference/standard deviation) relative to the mean. Genes are ranked based on the z-score (mean expression difference of
the respective gene between phenotype and control group/standard deviation). Affymetrix probe set ID, gene symbol and title is
provided for the differentially expressed genes
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show that (1) non-GC PTLD are a homogeneous group of
lymphoproliferations distinct from other B-NHL, as
assessed by gene expression profiling; (2) the gene
expression signature of non-GC PTLD is related to that
of activated memory B-cells; (3) PTLD progression is
associated with accrual of genetic lesions and (4) BCR
abnormalities in PTLD have a multifactorial etiology.
Non-GC PTLD are distinct from other B-NHL
subtypes
The relationship of PTLD to B-NHL of immunocompetent
hosts is unknown. In fact, B-cell M-PTLD are morpho-
logically indistinguishable from DLBCL (or BL), while
P-PTLD do not resemble any currently recognizable type
of B-NHL. Our comparative gene expression analysis of
PTLD with other types of B-NHL demonstrates that
non-GC PTLD have a homogeneous expression profile that
differs from that of other types of B-NHL, including
DLBCL (Figure 1). The histogenesis of GC PTLD could
not be addressed by our study; however, the single GC
PTLD in our series clustered with other GC type B-NHL of
immunocompetent hosts. The observation that, on super-
vised analysis, PTLD only showed differential upregula-
tion of transcription factors associated with plasma cell
differentiation [33] suggests similarities with activated
B-cell like DLBCL [34]. The DLBCL used in this study
were not classified into cell-of-origin-based subgroups
using a gene expression signature [34]. However, our
unsupervised analysis included immunoblastic lympho-
mas, a subset of which are known to have phenotypes
analogous to activated B-cell like DLBCL [35]. Thus, the
unique clustering of PTLD most likely reflects distinct
biologic features of these types of B-NHL.
PTLD also differ from DLBCL of immunocompetent
hosts with regard to associated genetic lesions, specifically
ASHM. The frequency of mutated post-transplant DLBCL
was lower compared to DLBCL of immunocompetent
hosts for all non-Ig genes except c-MYC and CIITA [6] (L.
P. unpublished data), and all genes showed a lower average
mutation frequency compared to de novo DLBCL [6].
Furthermore, no PIM1mutations were observed, similar to
an earlier report [5]. Overall, our data, in conjunction with
previous findings in PTLD and HIV-associated B-NHL,
suggest that immunosuppression-related lymphomas have
lower frequencies of ASHM [5,36].
Non-GC PTLD are related to activated
memory B-cells
Virtually, all clonal PTLD in our study appeared to arise
from antigen selected B-cells and the majority (74%) had
non-GC phenotypes. These data extend the results of prior
studies indicating derivation of PTLD from GC experi-
enced B-cells, which have the phenotype of pre-terminally
differentiated B-cells, that is BCL6þ//MUM1þ/
CD138 [2,7,8]. Of note, one P-PTLD lacked IgVH
mutations, but had BCL6 mutations. The latter, in the
absence of IgVH mutations, have previously been reported
in other types of B-NHL, including PTLD [2]. This could
reflect the stochastic nature of mutations targeting the two
different loci by SHM [37], suggesting GC transit in the
absence of Ig mutations.
Figure 3. Supervised analysis to identify differentially expressed genes between two groups of samples: (A) naı¨ve and memory B-cells
(N&M) compared to germinal centre (GC) B-cells; (B) naı¨ve B-cells compared to memory B-cells; (C) EBV-transformed lymphoblastoid
cell lines (LCL) compared to memory B-cells; (D) multiple myeloma cell lines (MM) compared to LCL. Expression of the selected genes
investigated in PTLD is depicted on the right side of each matrix. In the matrices, each row represents a gene and each column
represents a sample. Genes are ranked according to the z-score (mean expression difference of the gene between the phenotype group
and the control group/standard deviation). The scale bar represents differences in the z-score relative to the mean. (E) Cell type
classification to measure the relatedness of PTLDwith the investigated populations. The grey area marks the 95% of confidence: p-value
decreases with increasing distance from the X-axis
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When compared to normal B-cell subsets, gene
expression profiles of the non-GC PTLD were most
similar to those of resting memory B-cells (Figure 3B, E).
However, a comparison between PTLD, resting memory
B-cells and LCLs showed a closer similarity of PTLD with
LCLs (Figure 3C, E), which represent activated B-cells[38]
and have expression profiles similar to IgM-activated
B-cells [39]. Our findings, thus, support the hypothesis that
non-GC PTLD, both EBVþ and EBV, may derive from
an activated memory B-cell. The suggestion that some
PTLD are derived from memory B-cells was made by
Timms et al. [8] based on the presence of Ig mutations with
evidence of antigen selection. Previous studies had also
pointed to similarities in the phenotypes and latent viral
gene expression profiles between PTLD and LCLs or
tumours developing in SCID mice inoculated with EBV
infected human lymphocytes [40,41]. Since memory
B-cells serve as reservoirs of latent EBV infection [42],
it is conceivable that, in the setting of deregulated immune
surveillance, activation or acquisition of growth advantage
of cells within this compartment could result in a PTLD.
Relationships between different types of PTLD
Our results show that the gene expression programs of
P-PTLD and non-GC M-PTLD are indistinguishable, as
both unsupervised and supervised gene expression analyse
could not segregate them into two distinct groups. This
finding was somehow unexpected given the differences in
morphology, cellular composition, and genetic abnormal-
ities that characterize these two types of PTLD [1,3]. This
is also the case with ASHM, which appears to be rare in
P-PTLD but occurs in the majority of M-PTLD, as
shown by our and a previous study [5]. One possible
explanation for the inability of gene expression analysis to
separate P-PTLD and M-PTLD is the existence of
heterogeneity within one or both subtypes investigated.
The observation that distinct or different combinations of
genes are targeted by ASHM in different M-PTLD,
suggests biologic differences among cases. However, an
effect of subtle qualitative differences in cellular compo-
sition cannot be entirely excluded. If these assumptions are
true, then a significantly larger survey will be required to
identify distinct subsets within these two morphologic
categories.
It has been hypothesized that PTLD progress along a
continuum from polyclonal early lesions to monocloclonal
M-PTLD [1,43]. The identification of cytogenetic aberra-
tions common to both P-PTLD and M-PTLD supports this
view [4]. However, a direct relationship between P-PTLD
andM-PTLD has not been conclusively established. Only a
few studies have evaluated clonal relatedness of PTLD,
and clonal identity has been confirmed only in a handful of
recurrent M-PTLD and one recurrent P-PTLD [1,43–45].
Our analysis provides evidence of a clonal relationship
between a P-PTLD and a metachronous non-GC M-PTLD
for the first time, supporting a precursor–product
relationship between some P-PTLD and M-PTLD.
In our study, EBVþ and EBV PTLD did not show
significant differences in gene expression profiles,
suggesting a similar histogenesis of these PTLD subtypes.
This result is in contrast to a recent study by Craig et al.
who described differentially expressed genes, including
EBV regulated transcripts, among EBVþ and EBV
M-PTLD [46]. The differing results may be due to only a
few cases analysed in both studies, differences in the types
of cases evaluated or methodological differences in the
biostatistical analyses. We performed a stringent analysis
to identify only consistent differences among EBVþ and
EBV PTLD, using both P-PTLD andM-PTLD. The gene
expression differences among EBVþ and EBV cases
identified by Craig et al. require validation by generating a
classifier and testing them in an independent panel of cases,
to demonstrate robustness of the expression differences.
Clearly, larger series of PTLD of similar phenotypes need
to be analysed to determine differences or similarities
between EBVþ and EBV PTLD.
It also remains to be determined whether EBVþ and
EBV PTLD share aberrations of signalling cascades, cell
cycle regulators or proto-oncogenes, as has been suggested
for classical Hodgkin lymphoma (cHL) [47]. The observation
of an EBERþ M-PTLD that recurred as a clonally related
EBER M-PTLD, raises the possibility that certain EBV
PTLDmay result from ‘hit and run’ oncogenesis [48], similar
to EBV sporadic BL and cHL [49,50]. A comprehensive
survey to detect viral genomes in EBV PTLD is required to
definitively exclude a role of EBV or other viruses in the
pathogenesis of such lymphoproliferations.
Disease progression is associated with accrual
of genetic lesions
We could document accumulation of additional mutations
by the neoplastic clone in three recurrent PTLD (including
an M-PTLD representing progression of a prior P-PTLD).
These findings might reflect clonal heterogeneity at
inception, with survival of clones harbouring additional
advantageous mutations, or may result from ongoing
ASHM activity, as has been described for HIV-related
B-NHL [36]. The correlation between presence of ASHM
and AID expression by neoplastic cells makes the latter
tenable. Our data, in conjunction with prior studies,
suggest that progression of PTLD is associated with
accrual of genetic lesions [1,4,5]. We speculate that a
higher mutation frequency of non-Ig genes may connote
recalcitrant disease, similar to observations in B-NHL of
immunocompetent hosts [51]. However, larger series of
recurrent PTLD need to be studied to evaluate the impact
of ASHM on disease progression and prognosis.
B-cell receptor abnormalities in PTLD have a
multifactorial etiology
Our analysis showed absent or reduced sIgL expression by
flow cytometry in 32% of PTLD. While similar to earlier
studies [52,53], a more recent report described a higher
frequency of sIgL loss (76%) based on IHC staining [54].
These discrepancies may be due to lower sensitivity of
IHC-based methods compared to flow cytometry, as has
been reported for other B-NHL [55].
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Crippling IgVH gene mutations accounted for loss of
sIgL in only half of sIgL PTLD. In contrast to
observations in cHL [56], no loss of OCT2 expression
was seen in our sIgL PTLD, in accordance with a recent
report [57]. Absent PU.1 expression was seen in 4/6 (67%)
sIgL PTLD, confirming the observations of a recent study
[57]. This may be due to defective PU.1 expression, as
proposed [57], or it may reflect activation of a plasma cell
differentiation program [58]. Consistent with the latter
hypothesis, three of our sIgL PTLD showed phenotypic
evidence of transition to plasma cells, as evidenced by
CD20 downregulation, cytoplasmic light chain expression,
BLIMP-1 protein expression and/or CD43 expression (data
not shown).
Capello et al. recently reported crippling mutations
in IgL genes [54]. Since we did not analyse mutations in IgL
genes, it is unclear whether cytoplasmic light chain
expression, as observed in two of our sIgHþ sIgL PTLD,
is due to IgL gene mutations or other aberrations.
Expression of sIgH in the absence of sIgL has been
reported in LCLs and certain types of B-NHL [59–61]. The
etiology of this phenomenon appears multifactorial, some
of the proposed mechanisms include truncations in the VH
region secondary to abnormal splicing [59], post-
translational defects [62] and abnormal intracellular
transport [63].
Irrespective of the mechanism of BCR loss, immuno-
suppression may allow the survival of BCR-deficient
B-cells, as detected in recipients of solid organ allografts
[64]. In EBVþ PTLD, the virus itself may rescue B-cell
clones, which lack evidence of antigen selection or have
crippling Ig mutations [2,7,8], a hypothesis supported by
recent in vitro experiments [11]. However, the finding of
sIg EBV PTLD by us and others [54] suggests that as
yet unknown molecular alterations of the neoplastic cells
may allow survival of EBV BCR-deficient lymphocytes.
In summary, our findings indicate that non-GC PTLD
are distinct from other B-NHL and appear closely related
to activated memory B-cells. It is likely that distinct
morphologic categories of PTLD are biologically hetero-
geneous. Further studies are required to explore the
relationship of PTLD with other types of immunodefi-
ciency-associated B-NHL.
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